Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of acalabrutinib (± obinutuzumab) in Japanese adults with advanced B‑cell malignancies
jRCT2080223591Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability, Pharmacokinetics of acalabrutinib and 1 more. Started Jul 2017; status: completed.
02
Drugs
acalabrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)B-cell malignancy
Beyond the preview
Go deeper on jRCT2080223591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223591.